Welcome to our dedicated page for Fractyl Health news (Ticker: GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.
Fractyl Health, Inc. reports clinical and corporate developments as a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes. Its lead product candidate, Revita®, is a minimally invasive endoscopic therapy designed to remodel the duodenal lining for post-GLP-1 weight maintenance; it is investigational in the United States, has FDA Breakthrough Device designation, and is CE marked in the European Union and United Kingdom.
Company news also covers the Rejuva® AAV-based gene therapy platform, including RJVA-001 for type 2 diabetes and RJVA-002 for obesity, as well as clinical data from REMAIN-1, regulatory authorizations, financial results, capital-plan updates and public-company governance changes.
Fractyl Health (Nasdaq: GUTS) announced its Q1 2024 financial results, highlighting several key developments and milestones. The company reported revenues from its pilot commercial launch in Germany but faced increased R&D and SG&A expenses, leading to a net loss of $3.3 million. However, this was a significant improvement from the $11.9 million loss in Q1 2023, primarily due to a $17.1 million non-cash gain.
Fractyl expects to initiate the Remain-1 pivotal study for weight maintenance in H2 2024 and anticipates topline data from the Revitalize-1 study in Q4 2024. The company is also progressing with its Rejuva gene therapy program, aiming to present new preclinical data in May 2024 and complete IND-enabling studies by H2 2024. Additionally, Fractyl appointed Adrian Kimber as Chief Commercial Officer to lead launch readiness for Revita.
Fractyl’s cash position as of March 31, 2024, was $121.4 million, which is expected to fund operations through 2025. The company will discuss these updates in a conference call on May 13, 2024.
Fractyl Health, Inc. presented promising 6-month follow-up data from its German real-world registry study of Revita for advanced Type 2 Diabetes (T2D). Participants showed sustained improvements in blood glucose, weight loss, and reduced T2D medication use after a single treatment. No serious adverse events related to the device or procedure have been reported. These results indicate the potential of Revita for durable weight loss maintenance.
Fractyl Health, Inc. (Nasdaq: GUTS) will present at BofA Securities 2024 Health Care Conference. Dr. Harith Rajagopalan, CEO, will participate in a fireside chat on May 15, 2024. The Company focuses on innovative treatments for obesity and type 2 diabetes.
Fractyl Health, Inc. (Nasdaq: GUTS) will report Q1 2024 financial results and business updates on May 13, 2024. The company focuses on metabolic therapeutics for obesity and T2D, hosting a conference call at 4:30 p.m. ET.
Fractyl Health, Inc. (Nasdaq: GUTS) will present new data at the German Diabetes Association (DDG) Annual Meeting on its real-world registry study of Revita for T2D and at the Digestive Disease Week (DDW) on the potential of Rejuva in reducing liver fat. The presentations include clinical updates and preclinical data demonstrating the effectiveness of their metabolic therapeutics in treating obesity and T2D.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.